S&P 500   3,355.22 (+0.11%)
DOW   27,571.14 (-0.05%)
QQQ   276.84 (-0.13%)
AAPL   113.96 (-0.87%)
MSFT   209.47 (+0.01%)
FB   260.49 (+1.43%)
GOOGL   1,467.00 (+0.57%)
AMZN   3,165.47 (-0.27%)
TSLA   414.44 (-1.60%)
NVDA   521.00 (-0.08%)
BABA   277.18 (+0.42%)
CGC   14.33 (+0.84%)
MU   51.13 (+2.84%)
GE   6.14 (-0.97%)
AMD   80.05 (+0.72%)
T   28.29 (-0.32%)
F   6.62 (-1.05%)
ACB   4.69 (-1.88%)
GILD   62.37 (-0.76%)
NFLX   489.64 (-0.21%)
DIS   124.50 (-1.18%)
BA   162.60 (-2.10%)
BAC   23.79 (-1.25%)
S&P 500   3,355.22 (+0.11%)
DOW   27,571.14 (-0.05%)
QQQ   276.84 (-0.13%)
AAPL   113.96 (-0.87%)
MSFT   209.47 (+0.01%)
FB   260.49 (+1.43%)
GOOGL   1,467.00 (+0.57%)
AMZN   3,165.47 (-0.27%)
TSLA   414.44 (-1.60%)
NVDA   521.00 (-0.08%)
BABA   277.18 (+0.42%)
CGC   14.33 (+0.84%)
MU   51.13 (+2.84%)
GE   6.14 (-0.97%)
AMD   80.05 (+0.72%)
T   28.29 (-0.32%)
F   6.62 (-1.05%)
ACB   4.69 (-1.88%)
GILD   62.37 (-0.76%)
NFLX   489.64 (-0.21%)
DIS   124.50 (-1.18%)
BA   162.60 (-2.10%)
BAC   23.79 (-1.25%)
S&P 500   3,355.22 (+0.11%)
DOW   27,571.14 (-0.05%)
QQQ   276.84 (-0.13%)
AAPL   113.96 (-0.87%)
MSFT   209.47 (+0.01%)
FB   260.49 (+1.43%)
GOOGL   1,467.00 (+0.57%)
AMZN   3,165.47 (-0.27%)
TSLA   414.44 (-1.60%)
NVDA   521.00 (-0.08%)
BABA   277.18 (+0.42%)
CGC   14.33 (+0.84%)
MU   51.13 (+2.84%)
GE   6.14 (-0.97%)
AMD   80.05 (+0.72%)
T   28.29 (-0.32%)
F   6.62 (-1.05%)
ACB   4.69 (-1.88%)
GILD   62.37 (-0.76%)
NFLX   489.64 (-0.21%)
DIS   124.50 (-1.18%)
BA   162.60 (-2.10%)
BAC   23.79 (-1.25%)
S&P 500   3,355.22 (+0.11%)
DOW   27,571.14 (-0.05%)
QQQ   276.84 (-0.13%)
AAPL   113.96 (-0.87%)
MSFT   209.47 (+0.01%)
FB   260.49 (+1.43%)
GOOGL   1,467.00 (+0.57%)
AMZN   3,165.47 (-0.27%)
TSLA   414.44 (-1.60%)
NVDA   521.00 (-0.08%)
BABA   277.18 (+0.42%)
CGC   14.33 (+0.84%)
MU   51.13 (+2.84%)
GE   6.14 (-0.97%)
AMD   80.05 (+0.72%)
T   28.29 (-0.32%)
F   6.62 (-1.05%)
ACB   4.69 (-1.88%)
GILD   62.37 (-0.76%)
NFLX   489.64 (-0.21%)
DIS   124.50 (-1.18%)
BA   162.60 (-2.10%)
BAC   23.79 (-1.25%)
Log in
NASDAQ:JAZZ

Jazz Pharmaceuticals Stock Forecast, Price & News

$140.60
-0.89 (-0.63 %)
(As of 09/29/2020 09:57 AM ET)
Add
Compare
Today's Range
$140.09
Now: $140.60
$141.17
50-Day Range
$120.14
MA: $132.40
$144.13
52-Week Range
$86.88
Now: $140.60
$154.24
Volume885 shs
Average Volume709,766 shs
Market Capitalization$7.80 billion
P/E Ratio60.87
Dividend YieldN/A
Beta1.26
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also develops Solriamfetol for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea, as well as in Phase II clinical trial for EDS associated with Parkinson's disease; Vyxeos for acute myeloid leukemia; and JZP-258 to treat EDS and cataplexy with narcolepsy and potential treatment of idiopathic hypersomnia and a chronic neurological disorder. In addition, it sells psychiatry and other products. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; and XL-protein GmbH. The company is headquartered in Dublin, Ireland.
Read More
Jazz Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.81 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:JAZZ
CUSIPG5087110
Phone011-353-1634-7800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.16 billion
Cash Flow$22.25 per share
Book Value$54.99 per share

Profitability

Net Income$523.37 million

Miscellaneous

Employees1,620
Market Cap$7.80 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$140.60
-0.89 (-0.63 %)
(As of 09/29/2020 09:57 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive JAZZ News and Ratings via Email

Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions

How has Jazz Pharmaceuticals' stock price been impacted by Coronavirus?

Jazz Pharmaceuticals' stock was trading at $108.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, JAZZ stock has increased by 29.8% and is now trading at $140.25.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Jazz Pharmaceuticals?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Jazz Pharmaceuticals
.

When is Jazz Pharmaceuticals' next earnings date?

Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Jazz Pharmaceuticals
.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) issued its quarterly earnings results on Tuesday, August, 4th. The specialty pharmaceutical company reported $3.71 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $3.11 by $0.60. The specialty pharmaceutical company earned $562.44 million during the quarter, compared to analysts' expectations of $503.19 million. Jazz Pharmaceuticals had a net margin of 6.01% and a return on equity of 20.47%. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the company posted $4.05 earnings per share.
View Jazz Pharmaceuticals' earnings history
.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY20 earnings guidance on Tuesday, August, 4th. The company provided earnings per share (EPS) guidance of $11.90-13.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $11.96. The company issued revenue guidance of $2.225-2.325 billion, compared to the consensus revenue estimate of $2.20 billion.

What price target have analysts set for JAZZ?

18 equities research analysts have issued 12-month price targets for Jazz Pharmaceuticals' shares. Their forecasts range from $113.00 to $195.00. On average, they anticipate Jazz Pharmaceuticals' share price to reach $161.81 in the next year. This suggests a possible upside of 15.4% from the stock's current price.
View analysts' price targets for Jazz Pharmaceuticals
.

Are investors shorting Jazz Pharmaceuticals?

Jazz Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totaling 3,650,000 shares, an increase of 13.0% from the August 31st total of 3,230,000 shares. Based on an average daily volume of 778,200 shares, the days-to-cover ratio is presently 4.7 days. Approximately 6.8% of the company's stock are short sold.
View Jazz Pharmaceuticals' Short Interest
.

Who are some of Jazz Pharmaceuticals' key competitors?

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), AbbVie (ABBV), Tesla (TSLA), Biogen (BIIB) and Bank of America (BAC).

Who are Jazz Pharmaceuticals' key executives?

Jazz Pharmaceuticals' management team includes the following people:
  • Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO (Age 55)
  • Mr. Matthew P. Young, Exec. VP & CFO (Age 50)
  • Mr. Daniel N. Swisher Jr., Pres & COO (Age 56)
  • Ms. Karen J. Wilson, Sr. VP of Fin. & Principal Accounting Officer (Age 56)
  • Mr. Paul Treacy, Sr. VP of Technical Operations (Age 58)

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $140.25.

How big of a company is Jazz Pharmaceuticals?

Jazz Pharmaceuticals has a market capitalization of $7.78 billion and generates $2.16 billion in revenue each year. The specialty pharmaceutical company earns $523.37 million in net income (profit) each year or $14.60 on an earnings per share basis. Jazz Pharmaceuticals employs 1,620 workers across the globe.

What is Jazz Pharmaceuticals' official website?

The official website for Jazz Pharmaceuticals is www.jazzpharma.com.

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 011-353-1634-7800 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.